A MULTI-CENTRE NON-INTERVENTIONAL STUDY TO DESCRIBE THE EARLY CLINICAL EXPERIENCE OF AVELUMAB USED AS MONOTHERAPY FOR THE FIRST-LINE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE PROGRESSION-FREE FOLLOWING PLATINUM-BASED CHEMOTHERAPY
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Merck KGaA; Pfizer
Most Recent Events
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.
- 16 Jan 2024 Planned End Date changed from 9 May 2024 to 30 Nov 2024.
- 16 Jan 2024 Planned primary completion date changed from 1 Feb 2024 to 27 Jun 2024.